Order Article Reprints

Verma A, Chi Y-Y, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li H-T, Liang G, Leong R, Brown PA, et al. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers. 2024; 16(3):496. https://doi.org/10.3390/cancers16030496

Verma, Anupam, Yueh-Yun Chi, Jemily Malvar, Adam Lamble, Sonali Chaudhury, Archana Agarwal, Hong-Tao Li, Gangning Liang, Roy Leong, Patrick A. Brown, and et al. 2024. "Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium" Cancers 16, no. 3: 496. https://doi.org/10.3390/cancers16030496

Verma, A., Chi, Y.-Y., Malvar, J., Lamble, A., Chaudhury, S., Agarwal, A., Li, H.-T., Liang, G., Leong, R., Brown, P. A., Kaplan, J., Schafer, E. S., Slone, T., Pauly, M., Chang, B. H., Stieglitz, E., Wayne, A. S., Hijiya, N., & Bhojwani, D. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers, 16(3), 496. https://doi.org/10.3390/cancers16030496